Mary J G Zamboni, Carlos A P Cabral, Francisco J B Sampaio, Luiz E M Cardoso
{"title":"口服激素类避孕药影响年轻女性尿糖胺聚糖的浓度和组成。","authors":"Mary J G Zamboni, Carlos A P Cabral, Francisco J B Sampaio, Luiz E M Cardoso","doi":"10.1007/s00192-009-0948-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and hypothesis: </strong>Urinary glycosaminoglycans (uGAG) have protective effects against urinary tract disorders. Here we investigated whether oral hormonal contraceptives (OC) affect uGAG excretion.</p><p><strong>Methods: </strong>Urine specimens were from young women regularly taking: ethinyl estradiol + drospirenone, n = 9; ethinyl estradiol + cyproterone acetate, n = 9; and ethinyl estradiol + gestodene, n = 7. Controls were from ten women not taking OC. Total uGAG was assayed as hexuronic acid/urinary creatinine. Sulfated uGAG species was determined by electrophoresis.</p><p><strong>Results: </strong>Unlike controls, total uGAG in the two halves of the menstrual cycle was similar in the OC groups. Whole cycle uGAG was higher in the OC groups (p < 0.01), especially for ethinyl estradiol + cyproterone acetate (p < 0.005). The three OC produced decreases of approximately 50% in heparan sulfate (p < 0.02) and dermatan sulfate (p < 0.02), and a approximately 100% increase in chondroitin sulfate (p < 0.004).</p><p><strong>Conclusions: </strong>uGAG excretion is changed in women taking OC, and this might enhance the protective effects of these molecules against urinary tract disorders.</p>","PeriodicalId":73495,"journal":{"name":"International urogynecology journal and pelvic floor dysfunction","volume":"20 11","pages":"1353-9"},"PeriodicalIF":0.0000,"publicationDate":"2009-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s00192-009-0948-0","citationCount":"1","resultStr":"{\"title\":\"Oral hormonal contraceptives affect the concentration and composition of urinary glycosaminoglycans in young women.\",\"authors\":\"Mary J G Zamboni, Carlos A P Cabral, Francisco J B Sampaio, Luiz E M Cardoso\",\"doi\":\"10.1007/s00192-009-0948-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction and hypothesis: </strong>Urinary glycosaminoglycans (uGAG) have protective effects against urinary tract disorders. Here we investigated whether oral hormonal contraceptives (OC) affect uGAG excretion.</p><p><strong>Methods: </strong>Urine specimens were from young women regularly taking: ethinyl estradiol + drospirenone, n = 9; ethinyl estradiol + cyproterone acetate, n = 9; and ethinyl estradiol + gestodene, n = 7. Controls were from ten women not taking OC. Total uGAG was assayed as hexuronic acid/urinary creatinine. Sulfated uGAG species was determined by electrophoresis.</p><p><strong>Results: </strong>Unlike controls, total uGAG in the two halves of the menstrual cycle was similar in the OC groups. Whole cycle uGAG was higher in the OC groups (p < 0.01), especially for ethinyl estradiol + cyproterone acetate (p < 0.005). The three OC produced decreases of approximately 50% in heparan sulfate (p < 0.02) and dermatan sulfate (p < 0.02), and a approximately 100% increase in chondroitin sulfate (p < 0.004).</p><p><strong>Conclusions: </strong>uGAG excretion is changed in women taking OC, and this might enhance the protective effects of these molecules against urinary tract disorders.</p>\",\"PeriodicalId\":73495,\"journal\":{\"name\":\"International urogynecology journal and pelvic floor dysfunction\",\"volume\":\"20 11\",\"pages\":\"1353-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s00192-009-0948-0\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International urogynecology journal and pelvic floor dysfunction\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s00192-009-0948-0\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2009/7/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International urogynecology journal and pelvic floor dysfunction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00192-009-0948-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/7/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Oral hormonal contraceptives affect the concentration and composition of urinary glycosaminoglycans in young women.
Introduction and hypothesis: Urinary glycosaminoglycans (uGAG) have protective effects against urinary tract disorders. Here we investigated whether oral hormonal contraceptives (OC) affect uGAG excretion.
Methods: Urine specimens were from young women regularly taking: ethinyl estradiol + drospirenone, n = 9; ethinyl estradiol + cyproterone acetate, n = 9; and ethinyl estradiol + gestodene, n = 7. Controls were from ten women not taking OC. Total uGAG was assayed as hexuronic acid/urinary creatinine. Sulfated uGAG species was determined by electrophoresis.
Results: Unlike controls, total uGAG in the two halves of the menstrual cycle was similar in the OC groups. Whole cycle uGAG was higher in the OC groups (p < 0.01), especially for ethinyl estradiol + cyproterone acetate (p < 0.005). The three OC produced decreases of approximately 50% in heparan sulfate (p < 0.02) and dermatan sulfate (p < 0.02), and a approximately 100% increase in chondroitin sulfate (p < 0.004).
Conclusions: uGAG excretion is changed in women taking OC, and this might enhance the protective effects of these molecules against urinary tract disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
